

SLC16A3 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP12397b**Specification**

SLC16A3 Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [O15427](#)**SLC16A3 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 9123**Other Names**

Monocarboxylate transporter 4, MCT 4, Solute carrier family 16 member 3, SLC16A3, MCT4

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SLC16A3 Antibody (C-term) Blocking peptide - Protein Information**Name** SLC16A3**Synonyms** MCT3 {ECO:0000303|PubMed:9425115}, MCT4**Function**

Proton-dependent transporter of monocarboxylates such as L- lactate and pyruvate (PubMed:11101640, PubMed:23935841, PubMed:31719150). Plays a predominant role in L-lactate efflux from highly glycolytic cells (By similarity).

Cellular Location

Cell membrane; Multi-pass membrane protein. Basolateral cell membrane; Multi-pass membrane protein. Note=Plasma membrane localization is dependent upon the BSG/MCT4 interaction (PubMed:10921872). Basolateral sorting signals (BLSS) in C-terminal cytoplasmic tail ensure its basolateral expression in polarised epithelial cells (PubMed:21199217)

Tissue Location

Highly expressed in skeletal muscle.

SLC16A3 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

SLC16A3 Antibody (C-term) Blocking peptide - Images

SLC16A3 Antibody (C-term) Blocking peptide - Background

Lactic acid and pyruvate transport across plasma membranes is catalyzed by members of the proton-linked monocarboxylate transporter (MCT) family, which has been designated solute carrier family-16. Each MCT appears to have slightly different substrate and inhibitor specificities and transport kinetics, which are related to the metabolic requirements of the tissues in which it is found. The MCTs, which include MCT1 (SLC16A1; MIM 600682) and MCT2 (SLC16A7; MIM 603654), are characterized by 12 predicted transmembrane domains (Price et al., 1998 [PubMed 9425115]).

SLC16A3 Antibody (C-term) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Vellonen, K.S., et al. Eur J Pharm Sci 39(4):241-247(2010) Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009) Wang, Q., et al. Drug Metab. Dispos. 35(8):1393-1399(2007) Olsen, J.V., et al. Cell 127(3):635-648(2006)